e-learning
resources
Paris 2018
Monday, 17.09.2018
Clinical aspects of hypersensitivity pneumonitis (HP) and CTD-ILD: diagnosis, monitoring and treatment
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Clinical features of dermatitis, myositis and severe ILD. Could the AntiSSA / Ro52 antibodies be a diagnostic and prognostic tool for Antisyntatase syndrom?
P. KAVOURA (ATHENS, Greece), A. Frimas (ATHENS, Greece), P. Kithreotis (ATHENS, Greece), C. Bagos (ATHENS, Greece), S. Kanellas (ATHENS, Greece), D. Veldekis (ATHENS, Greece)
Source:
International Congress 2018 – Clinical aspects of hypersensitivity pneumonitis (HP) and CTD-ILD: diagnosis, monitoring and treatment
Session:
Clinical aspects of hypersensitivity pneumonitis (HP) and CTD-ILD: diagnosis, monitoring and treatment
Session type:
Thematic Poster
Number:
2995
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. KAVOURA (ATHENS, Greece), A. Frimas (ATHENS, Greece), P. Kithreotis (ATHENS, Greece), C. Bagos (ATHENS, Greece), S. Kanellas (ATHENS, Greece), D. Veldekis (ATHENS, Greece). Clinical features of dermatitis, myositis and severe ILD. Could the AntiSSA / Ro52 antibodies be a diagnostic and prognostic tool for Antisyntatase syndrom?. 2995
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Clinical and pathological findings of patients with interstitial lung diseases associated with antisynthetase other than Jo-1 antibodies
Source: Eur Respir J 2005; 26: Suppl. 49, 541s
Year: 2005
Clinical features and outcomes of patients with myositis associated-interstitial lung disease
Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases
Year: 2021
Severe sarcoidosis: clinical features and management
Source: Virtual Congress 2021 – Rare lung diseases 2021
Year: 2021
Clinical features of patients with sarcoidosis associated with Sjogren‘s syndrome
Source: Eur Respir J 2005; 26: Suppl. 49, 32s
Year: 2005
Interstitial pneumonia with autoimmune features associated with myositis autoantibodies: clinical characteristics from a multicenter Latin-American cohort.
Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside
Year: 2019
Utility of myositis related antibodies in interstitial lung disease and suspected autoimmunity.
Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new?
Year: 2019
Clinical significance of morphological indexes of inflammation and sclerosis in idiopathic fibrosing alveolitis (IFA) and lung sarcoidosis
Source: Eur Respir J 2002; 20: Suppl. 38, 107s
Year: 2002
Interstitial pneumonia with autoimmune features (IPAF): a clinical entity?
Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis
Year: 2019
Interstitial pneumonia with autoimmune features (IPAF): the relationship between radiological and clinical features
Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis
Year: 2020
Clinical manifestations of neurological involvement in sarcoidosis
- in our experience
Source: Eur Respir J 2004; 24: Suppl. 48, 711s
Year: 2004
Clinical features of interstitial lung disease in polymyositis and dermatomyositis
Source: Eur Respir J 2006; 28: Suppl. 50, 828s
Year: 2006
Undifferentiated systemic rheumatic diseases and overlap syndromes: when can we diagnose interstitial pneumonia with autoimmune features (IPAF)?
Source: International Congress 2018 – Respiratory medicine meets rheumatology
Year: 2018
Clinical features and CT findings of anti-Jo-1 antibody positive interstitial lung disease with or without polymyositis and dermatomyositis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease III
Year: 2013
Idiopathic non-specific interstitial pneumonia (NSIP): is it an autoimmune clinical entity?
Source: Annual Congress 2007 - Miscellaneous interstitial lung diseases related to systemic and other diseases
Year: 2007
Interstitial pneumonia with autoimmune features: applying novel diagnostic criteria to an existing patient cohort.
Source: International Congress 2017 – Novel and old entities
Year: 2017
ANCA associated vasculitis – Evaluation of diagnosis, treatment and outcome in a group of 68 patients
Source: International Congress 2014 – Clinical management of interstitial lung diseases and vasculitis
Year: 2014
HLA-DRB1* alleles and symptoms associated with Heerfordt's syndrome in sarcoidosis
Source: Eur Respir J 2011; 38: 1151-1157
Year: 2011
Clinical pearls and pitfalls
Source: Annual Congress 2005 - Difficult asthma in children
Year: 2005
Antinuclear antibodies and severe evolution of asthma
Source: Annual Congress 2007 - Towards controlling severe asthma
Year: 2007
Clinical utility of CCL15 as a prognostic biomarker for hypersensitivity pneumonitis
Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new?
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept